Antitrust review for BMS's Medarex deal expires
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has said that an antitrust review period has expired for its $2.4 billion acquisition of Medarex. The waiting period for Hart-Scott-Rodino review has passed, satisfying one of the conditions of BMS's tender offer.